AB&B BIO-TECH-B(02627)'s subsidiary WiseCornxin is the only vaccine selected for the preliminary review list of national medical insurance innovative drugs.
Zhonghui Biology-B (02627) announced that, according to the announcement issued by the National Medical Security Bureau on August 12, 2025...
AB&B BIO-TECH-B (02627) announced that according to the announcement released by the National Medical Security Administration on August 12, 2025, this year's national commercial health insurance innovative drug catalog includes the only vaccine product - quadrivalent influenza virus subunit vaccine.
The Group's product, named Huierkangxin quadrivalent influenza virus subunit vaccine, obtained a New Drug Application (NDA) approval from the China National Medical Products Administration in May 2023, and can be used for individuals aged three and above (with a specification of 15g/0.5ml in terms of virus strain hemagglutinin concentration). It is the first and only quadrivalent influenza virus subunit vaccine approved in China as of July 21, 2025, aiming to provide broad protection against two types of influenza A viruses (H1N1 and H3N2 subtypes) and two types of influenza B viruses (Yamagata and Victoria lineages). This product has undergone significant upgrades from traditional virus split vaccines, with advantages such as comprehensive protection, high purity of component antigens, and low risk of adverse reactions.
Related Articles
HK Stock Market Move | CHONGQING M&E (02722) rose by over 11% again, with an expected 50% increase in mid-term net profit compared to the same period last year. Rapidly growing demand for AIDC diesel engines.
HK Stock Market Move | KINTOR PHARMA-B(09939) rises more than 3% intra-day, GT20029 gel reaches primary endpoint in Phase II clinical trial for acne treatment.
HK Stock Market Move | ANTENGENE-B(06996) rose more than 14%. Claudin 18.2 ADC plans to be included in a groundbreaking therapy.
HK Stock Market Move | CHONGQING M&E (02722) rose by over 11% again, with an expected 50% increase in mid-term net profit compared to the same period last year. Rapidly growing demand for AIDC diesel engines.
HK Stock Market Move | KINTOR PHARMA-B(09939) rises more than 3% intra-day, GT20029 gel reaches primary endpoint in Phase II clinical trial for acne treatment.
HK Stock Market Move | ANTENGENE-B(06996) rose more than 14%. Claudin 18.2 ADC plans to be included in a groundbreaking therapy.
RECOMMEND
Virtually Unprecedented! U.S. Government’s Revenue Take from China-Bound Chip Exports Sparks Outcry, Multiple Policies Suspected as Revenue-Generation Measures
12/08/2025
Policy Continuity Catalyzes Market Potential Release; New Energy Vehicle Penetration Nears 50% in July
12/08/2025
Embodied Intelligence Applications Proliferate Across Industries; 2026 Poised to Mark the Inaugural Year of Mass Production
12/08/2025
